NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), PTC Therapeutics, Inc. (NASDAQ:PTCT), NGL Energy Partners LP (NYSE:NGL), Bemis Company, Inc. (NYSE:BMS), CorMedix Inc (NYSE:CRMD), and Patterson Companies, Inc. (NASDAQ:PDCO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
AVEO DOWNLOAD: http://Fundamental-Markets.com/register/?so=AVEO
PTCT DOWNLOAD: http://Fundamental-Markets.com/register/?so=PTCT
NGL DOWNLOAD: http://Fundamental-Markets.com/register/?so=NGL
BMS DOWNLOAD: http://Fundamental-Markets.com/register/?so=BMS
CRMD DOWNLOAD: http://Fundamental-Markets.com/register/?so=CRMD
PDCO DOWNLOAD: http://Fundamental-Markets.com/register/?so=PDCO
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), PTC Therapeutics, Inc. (NASDAQ:PTCT), NGL Energy Partners LP (NYSE:NGL), Bemis Company, Inc. (NYSE:BMS), CorMedix Inc (NYSE:CRMD), and Patterson Companies, Inc. (NASDAQ:PDCO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 5th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
AVEO PHARMACEUTICALS, INC. (AVEO) REPORT OVERVIEW
AVEO Pharmaceuticals' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, AVEO Pharmaceuticals reported revenue of $4.61MM vs $0.99MM (up 365.12%) and basic earnings per share -$0.22 vs -$0.07. For the twelve months ended December 31st, 2016 vs December 31st, 2015, AVEO Pharmaceuticals reported revenue of $2.52MM vs $19.02MM (down 86.78%) and basic earnings per share -$0.39 vs -$0.27. AVEO Pharmaceuticals is expected to report earnings on March 28th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.36 and is expected to report on March 28th, 2018.
To read the full AVEO Pharmaceuticals, Inc. (AVEO) report, download it here: http://Fundamental-Markets.com/register/?so=AVEO
-----------------------------------------
PTC THERAPEUTICS, INC. (PTCT) REPORT OVERVIEW
PTC Therapeutics' Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, PTC Therapeutics reported revenue of $41.85MM vs $22.99MM (up 82.08%) and basic earnings per share -$0.82 vs -$1.03. For the twelve months ended December 31st, 2016 vs December 31st, 2015, PTC Therapeutics reported revenue of $82.71MM vs $36.77MM (up 124.95%) and basic earnings per share -$4.17 vs -$5.07. PTC Therapeutics is expected to report earnings on March 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.78. The estimated EPS forecast for the next fiscal year is -$2.51 and is expected to report on March 6th, 2018.
To read the full PTC Therapeutics, Inc. (PTCT) report, download it here: http://Fundamental-Markets.com/register/?so=PTCT
-----------------------------------------
NGL ENERGY PARTNERS LP (NGL) REPORT OVERVIEW
NGL Energy Partners LP's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, NGL Energy Partners LP reported revenue of $4,463.26MM vs $3,406.64MM (up 31.02%) and basic earnings per share $0.33 vs -$0.07. For the twelve months ended March 31st, 2017 vs March 31st, 2016, NGL Energy Partners LP reported revenue of $13,022.23MM vs $11,742.11MM (up 10.90%) and basic earnings per share $0.99 vs -$2.35. NGL Energy Partners LP is expected to report earnings on May 24th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.14. The estimated EPS forecast for the next fiscal year is -$0.30 and is expected to report on May 24th, 2018.
To read the full NGL Energy Partners LP (NGL) report, download it here: http://Fundamental-Markets.com/register/?so=NGL
-----------------------------------------
BEMIS COMPANY, INC. (BMS) REPORT OVERVIEW
Bemis' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Bemis reported revenue of $1,003.60MM vs $988.00MM (up 1.58%) and basic earnings per share -$0.44 vs $0.65. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Bemis reported revenue of $4,046.20MM vs $4,004.40MM (up 1.04%) and basic earnings per share $1.03 vs $2.51 (down 58.96%). Bemis is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.58. The estimated EPS forecast for the next fiscal year is $3.11 and is expected to report on February 7th, 2019.
To read the full Bemis Company, Inc. (BMS) report, download it here: http://Fundamental-Markets.com/register/?so=BMS
-----------------------------------------
CORMEDIX INC (CRMD) REPORT OVERVIEW
CorMedix's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, CorMedix reported revenue of $0.06MM vs $0.04MM (up 37.30%) and basic earnings per share -$0.17 vs -$0.23. For the twelve months ended December 31st, 2016 vs December 31st, 2015, CorMedix reported revenue of $0.22MM vs $0.21MM (up 6.66%) and basic earnings per share -$0.65 vs -$0.58. CorMedix is expected to report earnings on March 15th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is -$0.27 and is expected to report on March 15th, 2018.
To read the full CorMedix Inc (CRMD) report, download it here: http://Fundamental-Markets.com/register/?so=CRMD
-----------------------------------------
PATTERSON COMPANIES, INC. (PDCO) REPORT OVERVIEW
Patterson Companies' Recent Financial Performance
For the three months ended October 31st, 2017 vs October 31st, 2016, Patterson Companies reported revenue of $1,385.74MM vs $1,418.24MM (down 2.29%) and basic earnings per share $0.43 vs $0.48 (down 10.42%). For the twelve months ended April 30th, 2017 vs April 30th, 2016, Patterson Companies reported revenue of $5,593.13MM vs $5,386.70MM (up 3.83%) and basic earnings per share $1.80 vs $1.93 (down 6.74%). Patterson Companies is expected to report earnings on May 24th, 2018. The report will be for the fiscal period ending April 30th, 2018. The reported EPS for the same quarter last year was $0.69. The estimated EPS forecast for the next fiscal year is $2.03 and is expected to report on May 24th, 2018.
To read the full Patterson Companies, Inc. (PDCO) report, download it here: http://Fundamental-Markets.com/register/?so=PDCO
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.